# Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies

> **NCT01206777** · PHASE2 · COMPLETED · sponsor: **Ohio State University Comprehensive Cancer Center** · enrollment: 52 (actual)

## Conditions studied

- Indolent or Intermediate Grade B-cell Malignancy

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT01206777
- **Lead sponsor:** Ohio State University Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2017-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01206777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01206777, "Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT01206777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*